Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsCash from RestructuringChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Lyra Therapeutics (LYRA) Capital Expenditures (2021 - 2025)

Lyra Therapeutics has reported Capital Expenditures over the past 5 years, most recently at $96000.0 for Q4 2025.

  • Quarterly results put Capital Expenditures at $96000.0 for Q4 2025, up 265.52% from a year ago — trailing twelve months through Dec 2025 was $2.4 million (up 1.37% YoY), and the annual figure for FY2025 was $116000.0, down 95.04%.
  • Capital Expenditures for Q4 2025 was $96000.0 at Lyra Therapeutics, up from -$58000.0 in the prior quarter.
  • Over the last five years, Capital Expenditures for LYRA hit a ceiling of $2.3 million in Q4 2021 and a floor of -$736000.0 in Q3 2021.
  • Median Capital Expenditures over the past 5 years was $93000.0 (2022), compared with a mean of $388588.2.
  • Peak annual rise in Capital Expenditures hit 2259.26% in 2024, while the deepest fall reached 502.82% in 2024.
  • Lyra Therapeutics' Capital Expenditures stood at $2.3 million in 2021, then crashed by 98.8% to $28000.0 in 2022, then surged by 2096.43% to $615000.0 in 2023, then crashed by 109.43% to -$58000.0 in 2024, then surged by 265.52% to $96000.0 in 2025.
  • The last three reported values for Capital Expenditures were $96000.0 (Q4 2025), -$58000.0 (Q4 2024), and $2.3 million (Q3 2024) per Business Quant data.